Júlia C Loureiro1, Marcos V Pais1, Florindo Stella1,2, Marcia Radanovic1, Antônio Lúcio Teixeira3,4, Orestes V Forlenza1, Leonardo Cruz de Souza5,6. 1. Laboratório de Neurociências LIM-27, Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo. 2. Instituto de Biociências, Universidade Estadual Paulista (UNESP), Rio Claro. 3. Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Texas, USA. 4. Santa Casa BH Ensino e Pesquisa. 5. Programa de Pós-Graduação em Neurociências, Universidade Federal de Minas Gerais (UFMG). 6. Departamento de Clínica Médica, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Brazil.
Abstract
PURPOSE OF REVIEW: Antiamyloid therapy of Alzheimer's disease tackles the overproduction and clearance of the amyloid-beta peptide (Aβ). Immunotherapeutic compounds were tested in large-scale trials. We revisit the recent literature focusing on randomized-controlled trials (RCT) using monoclonal anti-Aβ antibodies. RECENT FINDINGS: Forty-three articles on anti-Aβ passive immunotherapy for Alzheimer's disease were published between January 2016 and October 2019 regarding 17 RCTs: 13 phase III trials using the monoclonal antibodies bapineuzumab, solanezumab, gantenerumab, crenezumab, and aducanumab; three phase II with crenezumab and aducanumab; and one phase I trial with BAN2401. Studies resulted largely negative considering the effect of the treatment on primary and secondary outcome variables. The incidence of the most important adverse effect, amyloid-related imaging abnormalities (ARIAs) ranged between 0.2 and 22%, in treatment groups. Primary endpoints were not met in eight trials, and five trials were discontinued prior to completion. SUMMARY: Passive immunotherapy RCTs failed to show clinically relevant effects in patients with clinically manifest or prodromal dementia. The high incidence of ARIAs indicates that the risk of adverse events may outweigh the benefits of these interventions. Ongoing studies must determine the benefit of such interventions in preclinical Alzheimer's disease, addressing the effect of antiamyloid immunotherapy in samples of asymptomatic carriers of autosomal-dominant mutations related to early-onset Alzheimer's disease.
PURPOSE OF REVIEW: Antiamyloid therapy of Alzheimer's disease tackles the overproduction and clearance of the amyloid-beta peptide (Aβ). Immunotherapeutic compounds were tested in large-scale trials. We revisit the recent literature focusing on randomized-controlled trials (RCT) using monoclonal anti-Aβ antibodies. RECENT FINDINGS: Forty-three articles on anti-Aβ passive immunotherapy for Alzheimer's disease were published between January 2016 and October 2019 regarding 17 RCTs: 13 phase III trials using the monoclonal antibodies bapineuzumab, solanezumab, gantenerumab, crenezumab, and aducanumab; three phase II with crenezumab and aducanumab; and one phase I trial with BAN2401. Studies resulted largely negative considering the effect of the treatment on primary and secondary outcome variables. The incidence of the most important adverse effect, amyloid-related imaging abnormalities (ARIAs) ranged between 0.2 and 22%, in treatment groups. Primary endpoints were not met in eight trials, and five trials were discontinued prior to completion. SUMMARY: Passive immunotherapy RCTs failed to show clinically relevant effects in patients with clinically manifest or prodromal dementia. The high incidence of ARIAs indicates that the risk of adverse events may outweigh the benefits of these interventions. Ongoing studies must determine the benefit of such interventions in preclinical Alzheimer's disease, addressing the effect of antiamyloid immunotherapy in samples of asymptomatic carriers of autosomal-dominant mutations related to early-onset Alzheimer's disease.
Authors: Fadi Rofo; Silvio R Meier; Nicole G Metzendorf; Jamie I Morrison; Alex Petrovic; Stina Syvänen; Dag Sehlin; Greta Hultqvist Journal: Neurotherapeutics Date: 2022-08-08 Impact factor: 6.088
Authors: Mariko Sawa; Cassia Overk; Ann Becker; Dominique Derse; Ricardo Albay; Kim Weldy; Ahmad Salehi; Thomas G Beach; Eric Doran; Elizabeth Head; Y Eugene Yu; William C Mobley Journal: Alzheimers Dement Date: 2021-11-10 Impact factor: 16.655
Authors: Fadi Rofo; Jos Buijs; Ronny Falk; Ken Honek; Lars Lannfelt; Anna M Lilja; Nicole G Metzendorf; Tobias Gustavsson; Dag Sehlin; Linda Söderberg; Greta Hultqvist Journal: Transl Neurodegener Date: 2021-09-28 Impact factor: 8.014